Participants should agree to practice effective contraceptive precautions and to use at least one method of contraception for the duration of the study and for months post-transplant Agree to practice effective contraception Agree to practice highly effective barrier contraception during the entire study treatment period and through days after the last dose of the study drugs, OR Females and males of childbearing potential must agree to practice effective methods of contraception at the same time or agree to abstinence. Practice true abstinence or Female subjects of childbearing potential who agree to practice effective methods of contraception. Male subjects, even if surgically sterilized (i.e. Status post-vasectomy) must agree to agree to practice contraception. Agree to practice effective barrier contraception during the entire study Treatment period and through days after the last dose of study drug, OR Male subjects must agree to practice contraception Patients must not be pregnant/breast feeding and must agree to practice adequate contraception. Females and males of childbearing potential must agree to practice effective methods of contraception at the same time, or agree to abstinence Agree to practice effective contraception Women of childbearing potential and men should be advised and agree to practice effective methods of contraception during the course of study Agree to practice effective barrier contraception during the entire study treatment period and through days after the last dose of study drug, or Male subjects must agree to practice contraception Male subjects must agree to practice contraception Male subjects must agree to practice contraception Male subjects must agree to practice contraception. Inability to practice contraception with condoms as prescribed by the protocol Female patients who are of childbearing potential and all males must agree to practice true abstinence or use effective methods of contraception Subjects with reproductive capability must agree to practice adequate contraception methods. Subjects with reproductive capability must agree to practice adequate contraception methods. Male patients who agree to practice effective barrier contraception. Male patients at screening must agree to practice adequate contraception from study entry through at least months after discontinuation of study drug. Sexually active male patients unwilling to practice contraception while participating on the study and up to days after completion of treatment Male subjects must agree to practice contraception as directed Patients who do not agree to practice effective forms of contraception Patients of childbearing age who are unwilling to practice contraception Agree to practice effective barrier contraception during the entire study treatment period and through days after the last dose of study drug, AND Patients must be willing to practice effective contraception for the duration of the study Agree to practice highly effective barrier contraception during the entire study treatment period and through days after the last dose of study drug (or longer, as mandated by local labeling [example, USPI, SmPC, etc]), OR Agree to practice effective barrier contraception during the entire study treatment period and through months after the last dose of study drug, or All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and for up to weeks following the last dose of CC . Male subjects must agree to practice contraception during the study Agree to practice effective barrier contraception during the entire study treatment period and through months after the last dose of study drug, or Agree to practice effective barrier contraception during the entire study treatment period and through days after the last dose of study drug, AND Male subjects must agree to practice contraception Subjects with reproductive capability must agree to practice adequate contraception methods. Male subjects must agree to practice contraception Male subjects must agree to practice contraception Female subjects who are postmenopausal for at least year prior to screening. For women of child-bearing potential agree to practice effective methods of contraception, or agree to practice true abstinence Male subjects must agree to practice effective barrier contraception during the entire study treatment period and through days after last dose of study drug or practice true abstinence Female patients who are post menopausal, surgically sterile, or agree to practice effective methods of contraception or agree to practice true abstinence, and must also agree to ongoing pregnancy testing; must also adhere to the guidelines of the lenalidomide pregnancy prevention program Male patients who agree to practice effective barrier contraception or agree to practice true abstinence AND must adhere to the guidelines of the lenalidomide pregnancy prevention program Female participants who are post menopausal, surgically sterile, or agree to practice effective methods of contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant Male participants who agree to practice effective barrier contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant Patients must agree to practice adequate contraception. Female patients who are post menopausal for at least year, surgically sterile, or agree to practice effective methods of contraception through months after the last dose of study drug or agree to practice true abstinence Male patients who, even if surgically sterilized, agree to practice effective barrier contraception through months after the last dose of alisertib or agree to practice true abstinence Patients who cannot or do not intend to practice effective contraception Male participants agree to practice highly effective barrier contraception during the entire study treatment period and through days after the last dose of TAK- and, for docetaxel, for as long as is mandated by local labeling, or agree to practice true abstinence. Agree to practice effective barrier contraception during the entire study treatment period and through months after the last dose of study drug, or Agree to practice effective barrier contraception during the entire study treatment period and through months after the last dose of study drug, or All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile. Agree to practice effective barrier contraception during the entire study treatment period and through months after the last dose of study drug, or Agree to practice effective barrier contraception during the entire study treatment period and through months after the last dose of study drug, or Subjects with reproductive capability must agree to practice adequate contraception methods. Female patients who are post menopausal, surgically sterile, or agree to practice effective methods of contraception or agree to practice true abstinence Male patients who agree to practice effective barrier contraception or agree to practice true abstinence Female patients who are post menopausal, surgically sterile, or agree to practice effective methods of contraception through days after the last dose of study drug or agree to practice true abstinence Male patients who agree to practice effective barrier contraception through after the last dose of study drug or agree to practice true abstinence Female patients who are post menopausal, surgically sterile, or agree to practice effective methods of contraception or agree to practice true abstinence Male patients who agree to practice effective barrier contraception or agree to practice true abstinence Male subjects must agree to practice contraception Patients must agree to practice contraception Male subjects must agree to practice contraception All men and women must agree to practice effective contraception during the study period if not otherwise documented to be infertile. Agree to practice effective barrier contraception during the entire study treatment period and through days after the last dose of study drug, or Agree to practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to the use of highly effective methods of contraception from days prior to starting azacitidine, and must agree to continue using such precautions while taking azacitidine (including dose interruptions) and for up to days after the last dose of azacitidine. Cessation of contraception after this point should be discussed with a responsible physician Agree to practice effective barrier contraception during the entire study treatment period and through days after the last dose of study drug, or